IP Library Granted Patent US 9,775,823
Granted Patent B2
US 9,775,823 · App. 15/295,370 · Granted Oct 3, 2017

Prodrugs of fumarates and their use in treating various diseases

Inventors: Tarek A. Zeidan (Lexington, MA); Scott Duncan (Bedford, MA); Christopher P. Hencken (Boston, MA); Thomas Andrew Wynn (Lexington, MA); Carlos N. Sanrame (Lexington, MA)
Assignee: Alkermes Pharma Ireland Limited
A61K31/225C07D491/113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,775,823
App. No.
15/295,370
Granted
Oct 3, 2017
Kind
B2
Abstract

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

Claims (16)

1. A method of treating a disease, selected from multiple sclerosis and psoriasis, by administering to a subject in need thereof a therapeutically effective amount of the compound of formula (Ia) or a pharmaceutically acceptable salt thereof:

wherein:

R 1 is unsubstituted C 1 -C 6 alkyl;

L a is unsubstituted C 1 -C 6 alkyl linker; and

R 2 is H, unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, or unsubstituted C 2 -C 6 alkynyl.

2. The method of claim 1 , wherein R 1 is methyl.

3. The method of claim 1 , wherein L a is an unsubstituted C 1 -C 3 alkyl.

4. The method of claim 1 , wherein L a is an unsubstituted C 2 alkyl.

5. The method of claim 1 , wherein R 2 is an unsubstituted C 1 -C 3 alkyl.

6. The method of claim 1 , wherein R 2 is an unsubstituted C 1 -C 2 alkyl.

7. The method of claim 1 , wherein R 2 is methyl.

8. The method of claim 1 , wherein the compound is:

9. The method of claim 1 , wherein the disease is multiple sclerosis, and is further selected from relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, and progressive relapsing multiple sclerosis.

10. The method of claim 2 , wherein the disease is multiple sclerosis, and is further selected from relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, and progressive relapsing multiple sclerosis.

11. The method of claim 7 , wherein the disease is multiple sclerosis, and is further selected from relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, and progressive relapsing multiple sclerosis.

12. The method of claim 8 , wherein the disease is multiple sclerosis, and is further selected from relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, and progressive relapsing multiple sclerosis.

Assignments (6)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2019
From: ZEIDAN, TAREK A.; DUNCAN, SCOTT; HENCKEN, CHRISTOPHER P.; WYNN, THOMAS ANDREW; SANRAME, CARLOS N.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 051354/0700 →
SECURITY INTEREST Recorded Dec 4, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 047671/0386 →
SECURITY INTEREST Recorded Dec 19, 2016
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 040672/0937 →
Continuity (4)
Continuation 14212745 · Mar 14, 2014
Provisional Application 61934365 · Jan 31, 2014
Provisional Application 61782445 · Mar 14, 2013
Related Publication 20170095439A1 · Apr 6, 2017